Dhande Devshree, Dhok Archana, Anjankar Ashish, Nagpure Shailesh, Ganjare Roshani
Biochemistry, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Pharmacology, Dr. Rajendra Gode Medical College, Amravati, IND.
Cureus. 2024 Aug 13;16(8):e66772. doi: 10.7759/cureus.66772. eCollection 2024 Aug.
Sepsis is a critical condition characterized by a dysregulated immune response to infection, leading to systemic inflammation, multi-organ failure, and high mortality rates. Current treatments primarily involve antibiotics and supportive care, which address the infection and stabilize hemodynamics but do not directly modulate the inflammatory response. This limitation highlights the need for novel therapeutic approaches. This review aims to evaluate the role of (MIP) in sepsis management, focusing on its clinical outcomes and therapeutic potential. By examining preclinical and clinical evidence, we seek to understand the efficacy, safety, and practical applications of MIP in treating sepsis. A comprehensive review of existing literature was conducted, including preclinical studies, clinical trials, and case reports involving MIP. The review synthesizes findings related to its mechanism of action, therapeutic efficacy, and safety profile. MIP has demonstrated significant immunomodulatory effects, including enhancing innate and adaptive immune responses and reducing excessive inflammation. Clinical trials have shown promising results, with MIP improving clinical outcomes and reducing sepsis-related complications. The agent's unique ability to modulate the cytokine storm associated with sepsis positions it as a potential adjunctive therapy. MIP offers a novel approach to managing sepsis by addressing immune dysregulation and inflammation. The evidence suggests that MIP could be a valuable adjunct to current treatments, improving patient outcomes and addressing some limitations of conventional therapies. Further research is needed to establish its role in clinical practice and to optimize treatment protocols.
脓毒症是一种危急病症，其特征为对感染的免疫反应失调，导致全身炎症、多器官功能衰竭和高死亡率。当前的治疗主要包括使用抗生素和支持性护理，这些措施可应对感染并稳定血流动力学，但不能直接调节炎症反应。这一局限性凸显了对新型治疗方法的需求。本综述旨在评估（MIP）在脓毒症管理中的作用，重点关注其临床结果和治疗潜力。通过审查临床前和临床证据，我们试图了解MIP在治疗脓毒症方面的疗效、安全性和实际应用。我们对现有文献进行了全面综述，包括涉及MIP的临床前研究、临床试验和病例报告。该综述综合了与其作用机制、治疗效果和安全性概况相关的研究结果。MIP已显示出显著的免疫调节作用，包括增强固有免疫和适应性免疫反应以及减轻过度炎症。临床试验取得了令人鼓舞的结果，MIP改善了临床结果并减少了脓毒症相关并发症。该药物调节与脓毒症相关的细胞因子风暴的独特能力使其成为一种潜在的辅助治疗方法。MIP通过解决免疫失调和炎症问题，为脓毒症管理提供了一种新方法。证据表明，MIP可能是当前治疗的一种有价值的辅助手段，可改善患者预后并解决传统疗法的一些局限性。需要进一步研究以确定其在临床实践中的作用并优化治疗方案。
